Abstract:
The aim of the present investigation was to develop sustained release Glipizide matrix pellets for Type II diabetis mellitus. The Glipizide matrix pellets were prepared by extrusion-spheronization method using different hydrophilic polymers such as pectin, microcrystalline cellulose (MCC) and Eudragit L-100 in various proportions to retard and prolong the release of Glipizide. The prepared matrix pellets were characterized through Infrared Spectroscopy (FTIR), Differential Scanning Colorimetry (DSC), circularity, roundness, pellips, percent drug content, percent production yield, and in vitro drug release. The in vitro dissolution studies showed that GSR 6 formulation had released (90.07±0.67) the drug in a controlled profile for 12 h which containing pectin (30%), MCC PH-101 (35%), Eudragit L-100 (26%) and Polyvinylpyrrolidone (PVP) K-30 (5%) w/w. The DSC and FTIR studies revealed that there was no interaction between drug and excipients. Stability studies were carried out for optimized formulation GSR 6 according to ICH guidelines. Stability studies (40±20C/75±5% RH) for a period of 3 months indicated that Glipizide was stable in matrix pellets. In comparison, drug dissolution profile with marketed Glipizide (Glytop 10®) SR Tablet (98.23±0.88 % release), formulation GSR 6 drug release was found to be lesser up to 12 h. In conclusion, different hydrophilic polymers (Pectin, Microcrystalline Cellulose, Eudragit L-100 and Polyvinylpyrrolidone K-30) at optimum ratios in matrix pellets had a promising potential for sustained release.

Keywords: Glipizide, Extrusion-Spheronization, Pectin, Sustained Release Matrix Pellets, Pelletization.